Paratek Pharmaceuticals, Inc.

The United States Government As Represented by the Department of Veterans Affairs

Aventis Pharmaceuticals Inc.

Michael P Draper

Mark L Nelson

Stuart B Levy

Beena Bhatia

Todd Bowser

Oak K Kim

S Ken Tanaka

Laura Honeyman

Joel Berniac

Haregewein Assefa

Dennis P Molnar

Graham Jones

Michael Henry Cynamon

Paul R August

Katherine M Call

Judith N Steenbergen

Henry Long

Anna Wiencis Montmayeur

Pamela J Keagle

The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.

Methods of treating mycobacterial infections using tetracycline compounds

Methods of treating or preventing a bacterial infection in a subject are disclosed herein, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon. Also disclosed is a pharmaceutical composition comprising the compound of the present invention for treating or preventing a bacterial infection in a subject, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon.

Minocycline compounds for biodefense

A method for modulating RNA with tetracycline compounds is described.

Methods of using substituted tetracycline compounds to modulate RNA

Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.

Substituted tetracycline compounds for treatment of inflammatory skin disorders

Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.

Methods for treating spinal muscular atrophy using tetracycline compounds

This invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compositions which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compounds of the invention can be used to in combination with one or more anti-malarial compounds or can be used to treat or prevent malaria which is resistant to one or more other anti-malarial compounds.

Substituted tetracycline compounds for the treatment of malaria

Methods and compositions for treating for the synergistic treatment of fungal associated disorders are discussed.

Substituted tetracycline compounds as synergistic antifungal agents

The present invention relates to an automated method of transposon-mediated multiplex sequencing of DNA fragments inserted into a vector. It relates more particularity to an increased efficiency in such automated methods, where the increased efficiency is obtained by screening out before the sequencing those constructs in which the transposon inserted into the vector sequence. This prevents a waste of time and resources in performing reactions sequencing the vector instead of the DNA fragments of interest.

Transposon mediated multiplex sequencing

Methods and compositions for treating fungal associated disorders in subjects are discussed.

Growing community of inventors

Windham, NH, United States of America

Michael P Draper